Abstract
Purpose
To review the frequency of adverse events reported with nitrofurantoin (NF) in perimenopausal and menopausal women on prolonged daily prophylaxis in an outpatient setting.
Methods
Electronic medical records of women aged 50–95 prescribed NF by 2 primary urology providers for at least 3 consecutive months from 2006 to 2018 were retrospectively reviewed. Demographics, reason for the initiation, dose and duration of therapy, explanation of therapy interruptions, occurrence of adverse events, comorbid conditions, and relevant lab and imaging results were recorded. The number of months on prolonged therapy were summed.
Results
Of the 221 patients included, 167 (77%) were prescribed 100 mg of NF daily with a mean duration of therapy of 1.5 years. The most common indication for therapy was recurrent urinary tract infection prophylaxis. Breakthrough urinary tract infections developed in 88 (40%) patients on prolonged NF therapy but only 10 were not restarted on NF. Four patients (1.8%) were determined to have pulmonary adverse events and 1 (0.4%) developed elevated liver function tests.
Conclusion
In peri-menopausal and menopausal women, the risks and benefits of chronic NF therapy should be weighed by the clinician and patient prior to prescribing long term NF. Patients must be educated about the potential NF toxicities and clinically monitored for signs and symptoms of potential adverse events while on chronic NF therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(Suppl 1A):5S–13S
Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):e103–120
Foxman B, Gillespie B, Koopman J et al (2000) Risk factors for second urinary tract infection among college women. Am J Epidemiol 151(12):1194–1205
Ikaheimo R, Siitonen A, Heiskanen T et al (1996) Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 22(1):91–99
Dwyer PL, O'Reilly M (2002) Recurrent urinary tract infection in the female. Curr Opin Obstet Gynecol 14(5):537–543
Pittet D, Harbarth S, Ruef C et al (1999) Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland. Infect Control Hosp Epidemiol 20(1):37–42
Anger J, Lee U, Ackerman AL et al (2019) Re: recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol 202:282–289
Albert X, Huertas I, Pereiro II, Sanfelix J, Gosalbes V, Perrota C (2004) Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 3:CD001209
US Food and Drug Administration (2018) FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. US Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse. Accessed 15 Aug 2019
Deshpande A, Pasupuleti V, Thota P et al (2013) Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 68(9):1951–1961
Oplinger M, Andrews CO (2013) Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 47(1):106–111
American Geriatrics Society (2015) Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 63(11):2227–2246
By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society (2019) Updated AGS beers criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67(4):674–694
Conklin JD (1971) The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot Chemother 1978(25):233–252
Rego LL, Glazer CS, Zimmern PE (2016) Risks of long-term use of nitrofurantoin for urinary tract prophylaxis in the older patient. Urol Sci 27:193–198
Santos JM, Batech M, Pelter MA, Deamer RL (2016) Evaluation of the risk of nitrofurantoin lung injury and its efficacy in diminished kidney function in older adults in a large integrated healthcare system: a matched cohort study. J Am Geriatr Soc 64(4):798–805
Author information
Authors and Affiliations
Contributions
NNM, PEZ, BCP: protocol/project development; NNM: data collection or management; ALC, NNM, PEZ, BCP: data analysis; NNM, ALC, PEZ, BCP: manuscript writing/editing.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human or animal subjects performed by any of the authors. The data came from chart review.
Informed consent
We received IRB exemption due to chart review process. IRB: STU 04218–063/Recipient: Philippe E. Zimmern.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Maredia, N.N., Fanning, M.J., Christie, A.L. et al. Adverse effects of chronic nitrofurantoin therapy in women with recurrent urinary tract infections in an outpatient setting. World J Urol 39, 2597–2603 (2021). https://doi.org/10.1007/s00345-020-03464-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-020-03464-w